Last reviewed · How we verify
Dapagliflozin 10mg
At a glance
| Generic name | Dapagliflozin 10mg |
|---|---|
| Also known as | Farxiga, Forxiga®, Forxiga, SGLT2 inhibitor ; Forxiga, Placebo Matching Dapagliflozin 10mg |
| Sponsor | LG Chem |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
- The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure (NA)
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure (PHASE4)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus (PHASE4)
- Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease (PHASE2, PHASE3)
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin 10mg CI brief — competitive landscape report
- Dapagliflozin 10mg updates RSS · CI watch RSS
- LG Chem portfolio CI